Senseonics (NYSE:SENS) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus ...

Received FDA approval for Eversense® 365 Continuous Glucose Monitoring system and launched Eversense 365 with commercial ...

Highlights,FDA approval and US launch of Eversense® 365 CGM system drives 56% patient base growth.,Q4 2024 revenue reached $8 ...

Senseonics Holdings and Ascensia Diabetes Care announce the integration of SweetSpot with the Eversense 365 Continuous Glucose Monitoring (CGM) System in the U.S ...

Senseonics (NYSE:SENS – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $2.00 ...

Senseonics Holdings, Inc. ( NYSE: SENS) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and Chief Executive ...

GERMANTOWN, Md. (AP) — GERMANTOWN, Md. (AP) — Senseonics Holdings Inc. (SENS) on Monday reported a loss of $15.5 million in its fourth quarter. The Germantown, Maryland-based company said it ...

Brian Hansen, President of CGM at Ascensia Diabetes Care and a Director of Senseonics, remarked, “Since joining Ascensia’s CGM division a year ago, I’ve watched Senseonics deliver on its ...